Novartis | NVS - Stock


Novartis reported $6.42B in Stock for its fiscal quarter ending in September of 2025.





Stock Change Date
AbbVie USD 4.95B 13M Dec/2025
Amgen USD 6.22B 121M Dec/2025
AstraZeneca USD 6.59B 126M Sep/2025
Bausch Health Companies USD 1.6B 57M Sep/2025
Biogen USD 2.17B 41.3M Dec/2025
Bristol-Myers Squibb USD 2.76B 21M Sep/2025
Canopy Growth CAD 102.37M 8.55M Sep/2025
Corcept Therapeutics USD 12.87M 519K Dec/2025
Drreddys Laboratories INR 79.01B 3.41B Dec/2025
Eli Lilly USD 13.74B 1.56B Dec/2025
Gilead Sciences USD 1.78B 40M Sep/2025
GlaxoSmithKline GBP 6.12B 46M Sep/2025
Glaxosmithkline GBP 6.12B 46M Sep/2025
J&J USD 14.19B 45M Dec/2025
Merck USD 6.44B 157M Sep/2025
Novartis USD 6.42B 114M Sep/2025
Novartis USD 6.42B 114M Sep/2025
Pacira USD 157.68M 9.52M Sep/2025
Perrigo USD 1.23B 11.5M Sep/2025
Pfizer USD 11.47B 201M Sep/2025
Phibro Animal Health USD 517.35M 45.57M Dec/2025
Prestige Brands USD 163.59M 4.6M Dec/2025
Roche Holding CHF 7.6B 9M Jun/2025
Sanofi EUR 22.69B 1.81B Dec/2025
Sanofi EUR 22.69B 1.81B Dec/2025
Supernus Pharmaceuticals USD 107.1M 63.08M Sep/2025
Zoetis USD 2.43B 35M Dec/2025